Evidence map›Paper›PMID 41168893›Full record

ArticleBMB reports2025

Pluripotent stem cell-derived chimeric antigen receptor-natural killer cells targeting epidermal growth factor receptor 2 for cancer immunotherapy.

Jongsuk Han, Chaeyeon Jin, Sae-Byeok Hwang, In Jee Lee, Young Seok Baek, Daun Jung, Ki Yeon Kim, Shoukhrat Mitalipov, Ji Hyang Kim, Hee Jung An and 2 more

Abstract read
PubMed Full text at PMC
In one paragraph

Article in BMB reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jongsuk HanDepartment of Biomedical Science, College of Life Science, CHA University, Seongnam 13488, Korea.
Chaeyeon JinDepartment of Biomedical Science, College of Life Science, CHA University, Seongnam 13488, Korea.
Sae-Byeok HwangDepartment of Biomaterials Engineering, School of Medicine, and Biomedical Science, College of Life Science, CHA University, Seongnam 13488; CHA Medical Research Institute, CHA Bundang Medical Center, Seongnam 13488, Korea.
In Jee LeeDepartment of Biomaterials Engineering, School of Medicine, and Biomedical Science, College of Life Science, CHA University, Seongnam 13488, Korea.
Young Seok BaekDepartment of Biomaterials Engineering, School of Medicine, and Biomedical Science, College of Life Science, CHA University, Seongnam 13488, Korea.
Daun JungDepartment of Pathology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam 13496, Korea.
Ki Yeon KimDepartment of Pathology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam 13496, Korea.
Shoukhrat MitalipovCenter for Embryonic Cell and Gene Therapy, Oregon Health and Science University, Portland, OR 97239, USA.
Ji Hyang KimDepartment of Obstetrics and Gynecology, CHA Bundang Medical Center, School of Medicine, CHA University, Seongnam 13496, Korea.
Hee Jung AnDepartment of Pathology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam 13496, Korea.
Yeonmi LeeCHA Medical Research Institute, CHA Bundang Medical Center, Seongnam 13488, Korea.
Eunju KangDepartment of Biomedical Science, College of Life Science, CHA University, Seongnam 13488; CHA Medical Research Institute, CHA Bundang Medical Center, Seongnam 13488; Department of Biochemistry, School of Medicine, CHA University, Seongnam 13488, Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chimeric antigen receptor-natural killer (CAR-NK) cells are emerging as a promising platform for allogeneic, cell-based immunotherapy. Among available sources, NK cells derived from pluripotent stem cells (PSCs) provide a renewable and scalable option that overcomes the limitations of primary NK cells. Human epidermal growth factor receptor 2 (HER2), a membrane protein frequently overexpressed in many solid tumors, is an attractive target for cancer immunotherapy. In this study, we designed a green fluorescent protein (GFP)-linked anti-HER2 CAR construct and introduced it into PSCs via lentiviral transduction. Three stable PSC-derived clones (CAR-A, CAR-B, and CAR-C) were established, each co-expressing anti-HER2 CAR with GFP. After differentiation under xeno-free and feeder-free culture conditions, CAR expression was maintained in NK cells. The resulting PSC-derived CAR-NK cells displayed phenotypic and functional features comparable to wild-type PSC-derived NK cells, while showing markedly enhanced cytotoxicity against HER2-positive cancer cell lines. These findings demonstrated the potential of the use of PSC-derived anti-HER2 CAR-NK cells as a robust and scalable immunotherapy. In addition, this platform could be extended to produce CAR-NK cells directed against a wide range of tumorassociated antigens. [BMB Reports 2025; 58(11): 475-483].

Indexed as

Erb-b2 Receptor Tyrosine KinasesImmunotherapyKiller Cells, NaturalNeoplasmsPluripotent Stem CellsReceptors, Chimeric AntigenCell DifferentiationCell Line, TumorHumansImmunotherapy, AdoptiveERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, Chimeric Antigen

Identifiers

PMID41168893
PMCPMC12665497

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.